GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Serum Bio Technology Co Ltd (SHSE:688163) » Definitions » Debt-to-Revenue

Shanghai Serum Bio Technology Co (SHSE:688163) Debt-to-Revenue : 0.13 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shanghai Serum Bio Technology Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Serum Bio Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.8 Mil. Shanghai Serum Bio Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥12.4 Mil. Shanghai Serum Bio Technology Co's annualized Revenue for the quarter that ended in Mar. 2024 was ¥105.2 Mil. Shanghai Serum Bio Technology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.12.


Shanghai Serum Bio Technology Co Debt-to-Revenue Historical Data

The historical data trend for Shanghai Serum Bio Technology Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Serum Bio Technology Co Debt-to-Revenue Chart

Shanghai Serum Bio Technology Co Annual Data
Trend Dec13 Dec14 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.08 0.07 0.08 0.07

Shanghai Serum Bio Technology Co Quarterly Data
Dec16 Dec17 Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.05 0.05 0.14 0.13

Competitive Comparison of Shanghai Serum Bio Technology Co's Debt-to-Revenue

For the Biotechnology subindustry, Shanghai Serum Bio Technology Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Serum Bio Technology Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Serum Bio Technology Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Serum Bio Technology Co's Debt-to-Revenue falls into.



Shanghai Serum Bio Technology Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Serum Bio Technology Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.758 + 12.2) / 190.144
=0.07

Shanghai Serum Bio Technology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.758 + 12.356) / 105.204
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Shanghai Serum Bio Technology Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Serum Bio Technology Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Serum Bio Technology Co (SHSE:688163) Business Description

Traded in Other Exchanges
N/A
Address
No. 1288, Huaqing Road, Qingpu District, Shanghai, CHN, 201707
Shanghai Serum Bio Technology Co Ltd is engaged in the research, development, production and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety.

Shanghai Serum Bio Technology Co (SHSE:688163) Headlines

No Headlines